American Association for Cancer Research
Browse
23266066cir170490-sup-188798_1_supp_4400709_kzqgwl.pdf (1.61 MB)

Figure S4 from IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells

Download (1.61 MB)
journal contribution
posted on 2023-04-03, 23:25 authored by Eleanor Clancy-Thompson, Lestat Ali, Patrick T. Bruck, Mark A. Exley, Richard S. Blumberg, Glenn Dranoff, Michael Dougan, Stephanie K. Dougan

S4: CD1d knockout mice show a significant contribution of the costimulatory effects of LBW-242 on cytokine production by CD4+ T cells.

Funding

Dana-Farber Cancer Institute

Claudia Adams Barr Foundation and the Melanoma Research Alliance

Kirschstein National Research Service

NIH

History

ARTICLE ABSTRACT

Inhibitor of apoptosis protein (IAP) antagonists are in clinical trials for a variety of cancers, and mouse models show synergism between IAP antagonists and anti–PD-1 immunotherapy. Although IAP antagonists affect the intrinsic signaling of tumor cells, their most pronounced effects are on immune cells and the generation of antitumor immunity. Here, we examined the effects of IAP antagonism on T-cell development using mouse fetal thymic organ culture and observed a selective loss of iNKT cells, an effector cell type of potential importance for cancer immunotherapy. Thymic iNKT-cell development probably failed due to increased strength of TCR signal leading to negative selection, given that mature iNKT cells treated with IAP antagonists were not depleted, but had enhanced cytokine production in both mouse and human ex vivo cultures. Consistent with this, mature mouse primary iNKT cells and iNKT hybridomas increased production of effector cytokines in the presence of IAP antagonists. In vivo administration of IAP antagonists and α-GalCer resulted in increased IFNγ and IL-2 production from iNKT cells and decreased tumor burden in a mouse model of melanoma lung metastasis. Human iNKT cells also proliferated and increased IFNγ production dramatically in the presence of IAP antagonists, demonstrating the utility of these compounds in adoptive therapy of iNKT cells. Cancer Immunol Res; 6(1); 25–35. ©2017 AACR.

Usage metrics

    Cancer Immunology Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC